Form D · Biotechnology

EnPlusOne Biosciences Inc.

Watertown, MA · CIK 0001946593

Offering snapshot reported Dec 26, 2024 · SEC filing

Reported sold: $21.8M
Investors reported: 7
Minimum accepted: $0
First sale: Dec 9, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$12,896,707 → $21,816,706
Reported investors6 → 7

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 26, 2024	Amendment	$12,896,707	$1,000,002vs Oct 3, 2022	6	SEC filing
Dec 26, 2024	Amendment	$21,816,706	$8,919,999vs Dec 26, 2024	7	SEC filing
Oct 3, 2022	Initial	$11,896,705	No comparison	6	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-460553

The total offering amount and the total amount sold include the conversion of $1,296,705 of outstanding convertible securities.

Source: Form D, filed Dec 26, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Daniel Ahlstedt	Director, Executive
Daniel Janse	Director
Steven Kasok	Director
Andrew Lee	Director
Paxton Major	Director
Daniel Wiegand	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

313 Pleasant Street 4 W
Watertown, MA, 02472